Prolyl carboxypeptidase and its inhibitors in metabolism

Trends in Endocrinology and Metabolism

Volumn 24, Issue 2, 2013, Pages 61-67

  Jeong, Jin Kwon ^a   Diano, Sabrina ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Enzymatic inhibitors; Food intake; Hypothalamus; Prolyl carboxypeptidase; Proopiomelanocortin

Indexed keywords

AMIDE; ENT 3A; PEPTIDE HYDROLASE INHIBITOR; PROLINE CARBOXYPEPTIDASE; PROLYL CARBOXYPEPTIDASE INHIBITOR; UM8190; UNCLASSIFIED DRUG;

ARCUATE NUCLEUS; CHEMICAL MODIFICATION; DRUG BIOAVAILABILITY; ENERGY EXPENDITURE; ENERGY METABOLISM; ENZYME ACTIVITY; FOOD INTAKE; HUMAN; METABOLIC REGULATION; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION;

AMINOPEPTIDASES; EATING; ENZYME INHIBITORS; HUMANS; HYPOTHALAMUS; PRO-OPIOMELANOCORTIN;

EID: 84873132469     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2012.11.001     Document Type: Review

References (59)

1. Benoit S.C., et al. The catabolic action of insulin in the brain is mediated by melanocortins. J. Neurosci. 2002, 22:9048-9052.
2. Mihaly E., et al. Hypophysiotropic thyrotropin-releasing hormone-synthesizing neurons in the human hypothalamus are innervated by neuropeptide Y, agouti-related protein, and alpha-melanocyte-stimulating hormone. J. Clin. Endocrinol. Metab. 2000, 85:2596-2603.
3. Plum L., et al. Central insulin action in energy and glucose homeostasis. J. Clin. Invest. 2006, 116:1761-1766.
4. Schwartz M.W., et al. Central nervous system control of food intake. Nature 2000, 404:661-671.
5. Fekete C., et al. Alpha-melanocyte-stimulating hormone is contained in nerve terminals innervating thyrotropin-releasing hormone-synthesizing neurons in the hypothalamic paraventricular nucleus and prevents fasting-induced suppression of prothyrotropin-releasing hormone gene expression. J. Neurosci. 2000, 20:1550-1558.
6. Hill J.W., et al. Acute effects of leptin require PI3K signaling in hypothalamic proopiomelanocortin neurons in mice. J. Clin. Invest. 2008, 118:1796-1805.
7. Mizuno T.M., et al. Hypothalamic pro-opiomelanocortin mRNA is reduced by fasting in ob/ob and db/db mice, but is stimulated by leptin. Diabetes 1998, 47:294-297.
8. Tung Y.C., et al. A comparative study of the central effects of specific proopiomelancortin (POMC)-derived melanocortin peptides on food intake and body weight in Pomc null mice. Endocrinology 2006, 147:5940-5947.
9. Yeo G.S., et al. The role of melanocortin signalling in the control of body weight: evidence from human and murine genetic models. QJM 2000, 93:7-14.
10. Young J.I., et al. Authentic cell-specific and developmentally regulated expression of pro-opiomelanocortin genomic fragments in hypothalamic and hindbrain neurons of transgenic mice. J. Neurosci. 1998, 18:6631-6640.
11. Cone R.D. Anatomy and regulation of the central melanocortin system. Nat. Neurosci. 2005, 8:571-578.
12. Fan W., et al. Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature 1997, 385:165-168.
13. Huszar D., et al. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 1997, 88:131-141.
14. Seeley R.J., et al. Melanocortin receptors in leptin effects. Nature 1997, 390:349.
15. Chiesi M., et al. Pharmacotherapy of obesity: targets and perspectives. Trends Pharmacol. Sci. 2001, 22:247-254.
16. Butler A.A., et al. A unique metabolic syndrome causes obesity in the melanocortin-3 receptor-deficient mouse. Endocrinology 2000, 141:3518-3521.
17. Chen A.S., et al. Inactivation of the mouse melanocortin-3 receptor results in increased fat mass and reduced lean body mass. Nat. Genet. 2000, 26:97-102.
18. Liu H., et al. Transgenic mice expressing green fluorescent protein under the control of the melanocortin-4 receptor promoter. J. Neurosci. 2003, 23:7143-7154.
19. Mountjoy K.G., et al. Localization of the melanocortin-4 receptor (MC4-R) in neuroendocrine and autonomic control circuits in the brain. Mol. Endocrinol. 1994, 8:1298-1308.
20. Cowley M.A., et al. Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus. Nature 2001, 411:480-484.
21. Jegou S., et al. Melanocortin-3 receptor mRNA expression in pro-opiomelanocortin neurones of the rat arcuate nucleus. J. Neuroendocrinol. 2000, 12:501-505.
22. De Souza F.S., et al. The estrogen receptor α colocalizes with proopiomelanocortin in hypothalamic neurons and binds to a conserved motif present in the neoron-specific enhancer nPE2. Eur. J. Pharmacol. 2011, 11:181-187.
23. Roepke T.A., et al. Serotonin 5-HT2C receptor-mediated inhibition of the M-current in hypothalamic POMC neurons. Am. J. Physiol. Endocrinol. Metab. 2012, 302:1399-1406.
24. Wauman J., et al. Leptin receptor signaling: pathways to leptin resistance. Front. Biosci. 2011, 16:2771-2793.
25. Pritchard L.E., et al. Pro-opiomelanocortin processing in the hypothalamus: impact on melanocortin signalling and obesity. J. Endocrinol. 2002, 172:411-421.
26. Wardlaw S.L. Hypothalamic proopiomelanocortin processing and the regulation of energy balance. Eur. J. Pharmacol. 2011, 660:213-219.
27. Wallingford N., et al. Prolylcarboxypeptidase regulates food intake by inactivating alpha-MSH in rodents. J. Clin. Invest. 2009, 119:2291-2303.
28. Jeong J.K., et al. Prolyl carboxypeptidase regulates energy expenditure and the thyroid axis. Endocrinology 2012, 153:683-689.
29. Jeong J.K., et al. Deletion of prolyl carboxypeptidase attenuates the metabolic effects of diet-induced obesity. Am. J. Physiol. Endocrinol. Metab. 2012, 302:E1502-E1510.
30. Tan F., et al. Sequencing and cloning of human prolylcarboxypeptidase (angiotensinase C). Similarity to both serine carboxypeptidase and prolylendopeptidase families. J. Biol. Chem. 1993, 268:16631-16638.
31. Abeywickrema P.D., et al. Expression, purification and crystallization of human prolylcarboxypeptidase. Acta Crystallogr. Sect. F: Struct. Biol. Cryst. Commun. 2010, 66:702-705.
32. Soisson S.M., et al. Structural definition and substrate specificity of the S28 protease family: the crystal structure of human prolylcarboxypeptidase. BMC Struct. Biol. 2010, 10:16.
33. Kumamoto K., et al. Prolylcarboxypeptidase (angiotensinase C) in human lung and cultured cells. J. Clin. Invest. 1981, 67:210-215.
34. Yang H.Y., et al. New enzymatic route for the inactivation of angiotensin. Nature 1968, 218:1224-1226.
35. Miller J.J., et al. Angiotensin carboxypeptidase activity in urine from normal subjects and patients with kidney damage. Life Sci. 1991, 48:1529-1535.
36. Mallela J., et al. The functional importance of the N-terminal region of human prolylcarboxypeptidase. Biochem. Biophys. Res. Commun. 2008, 374:635-640.
37. Mallela J., et al. Prolylcarboxypeptidase: a cardioprotective enzyme. Int. J. Biochem. Cell Biol. 2009, 41:477-481.
38. Adams G.N., et al. Murine prolylcarboxypeptidase depletion induces vascular dysfunction with hypertension and faster arterial thrombosis. Blood 2011, 117:3929-3937.
39. Zhang Y., et al. E112D polymorphism in the prolylcarboxypeptidase gene is associated with blood pressure response to benazepril in Chinese hypertensive patients. Chin. Med. J. 2009, 122:2461-2465.
40. Greenfield J.R., et al. Modulation of blood pressure by central melanocortinergic pathways. N. Engl. J. Med. 2009, 360:44-52.
41. Tallam L.S., et al. Melanocortin-4 receptor-deficient mice are not hypertensive or salt-sensitive despite obesity, hyperinsulinemia, and hyperleptinemia. Hypertension 2005, 46:326-332.
42. Ngo M.L., et al. Upregulation of prolylcarboxypeptidase (PRCP) in lipopolysaccharide (LPS) treated endothelium promotes inflammation. J. Inflamm. 2009, 6:3.
43. Brzoska T., et al. Terminal signal: anti-inflammatory effects of α-melanocyte-stimulating hormone related peptides beyond the pharmacophore. Adv. Exp. Med. Biol. 2010, 681:107-116.
44. Xu S., et al. Plasma prolylcarboxypeptidase (angiotensinase C) is increased in obesity and diabetes mellitus and related to cardiovascular dysfunction. Clin. Chem. 2012, 58:1110-1115.
45. McCarthy J.J., et al. Evidence for substantial effect modification by gender in a large-scale genetic association study of the metabolic syndrome among coronary heart disease patients. Hum. Genet. 2003, 114:87-98.
46. Diano S. New aspects of melanocortin signaling: a role for PRCP in alpha-MSH degradation. Front. Neuroendocrinol. 2011, 32:70-83.
47. Jegou S., et al. Melanocortin-3 receptor mrna expression in proopiomelanocortin neurons of the rat arcuate nucleus. J. Neuroendocrinol. 2000, 12:501-505.
48. Mark D.L., et al. The regulation of food intake by selective stimulation of the type 3 melanocortin receptor (MC3R). Peptides 2006, 27:259-264.
49. Shariat-Madar B., et al. Prolylcarboxypeptidase (PRCP) as a new target for obesity treatment. Diabetes Metab. Syndr. Obes. 2010, 3:67-78.
50. Zhou C., et al. Design and synthesis of prolylcarboxypeptidase (PrCP) inhibitors to validate PrCP as a potential target for obesity. J. Med. Chem. 2010, 53:7251-7263.
51. Shen H.C., et al. Discovery of benzimidazole pyrrolidinyl amides as prolylcarboxypeptidase inhibitors. Bioorg. Med. Chem. Lett. 2011, 21:1299-1305.
52. Maryanoff B.E. Inhibitors of serine proteases as potential therapeutic agents. J. Med. Chem. 2004, 47:769-787.
53. Graham T.H., et al. A new class of prolylcarboxypeptidase inhibitors, part 1: discovery and evaluation. Bioorg. Med. Chem. Lett. 2012, 22:2811-2817.
54. Graham T.H., et al. A new class of prolylcarboxypeptidase inhibitors, part 2: the aminocyclopentanes. Bioorg. Med. Chem. Lett. 2012, 22:2818-2822.
55. Rabey F.M., et al. Influence of a novel inhibitor (UM8190) of prolylcarboxypeptidase (PRCP) on appetite and thrombosis. Curr. Med. Chem. 2012, 19:4194-4206.
56. Graham T.H., et al. The discovery of non-benzimidazole and brain-penetrant prolylcarboxypeptidase inhibitors. Bioorg. Med. Chem. Lett. 2012, 22:658-665.
57. Shen H.C., et al. Discovery of benzodihydroisofurans as novel, potent, bioavailable and brain-penetrant prolylcarboxypeptidase inhibitors. Bioorg. Med. Chem. Lett. 2012, 22:1550-1556.
58. Wu Z., et al. Discovery of aminoheterocycles as potent and brain penetrant prolylcarboxypeptidase inhibitors. Bioorg. Med. Chem. Lett. 2012, 22:1727-1730.
59. Wu Z., et al. Discovery of a new class of potent prolylcarboxypeptidase inhibitors derived from alanine. Bioorg. Med. Chem. Lett. 2012, 22:1774-1778.